Diversified Trust Co Decreases Holdings in Edwards Lifesciences Corporation $EW

Diversified Trust Co decreased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 45.7% during the 1st quarter, HoldingsChannel.com reports. The fund owned 20,057 shares of the medical research company’s stock after selling 16,910 shares during the period. Diversified Trust Co’s holdings in Edwards Lifesciences were worth $1,606,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in EW. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $25,000. MV Capital Management Inc. bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $26,000. Kemnay Advisory Services Inc. bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $27,000. Kohmann Bosshard Financial Services LLC purchased a new position in Edwards Lifesciences in the fourth quarter valued at approximately $28,000. Finally, Hilton Head Capital Partners LLC purchased a new position in Edwards Lifesciences in the fourth quarter valued at approximately $28,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president directly owned 98,611 shares in the company, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the sale, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 81,038 shares of company stock valued at $6,683,255 in the last ninety days. 0.31% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on EW. Mizuho set a $95.00 price objective on Edwards Lifesciences and gave the company an “outperform” rating in a report on Monday, April 13th. BTIG Research boosted their target price on Edwards Lifesciences from $98.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Finally, Barclays reissued an “overweight” rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average price target of $95.96.

Edwards Lifesciences Stock Down 1.9%

EW opened at $85.72 on Tuesday. The company has a 50 day moving average of $83.52 and a 200 day moving average of $83.13. The company has a market cap of $49.36 billion, a PE ratio of 45.59, a price-to-earnings-growth ratio of 2.19 and a beta of 0.87. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $89.60. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. During the same period in the previous year, the business earned $0.64 EPS. Edwards Lifesciences’s revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.